# Oruka Therapeutics Inc. (ORKA)

Source: https://www.quantisnow.com/company/ORKA
Generated: 2026-11-11T20:13:23.773Z

- Ticker: ORKA
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances
- SEC CIK: 0000907654

## Latest ORKA news and filings

- 2026-11-09 21:04 UTC [Earnings] [Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update](https://www.quantisnow.com/insight/oruka-therapeutics-reports-third-quarter-2026-financial-results-and-provides-6781111)
- 2026-11-09 21:02 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Oruka Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-oruka-therapeutics-inc-6781095)
- 2026-11-03 12:00 UTC [Conference Announcement] [Oruka Therapeutics to Participate in Multiple Upcoming Conferences](https://www.quantisnow.com/insight/oruka-therapeutics-to-participate-in-multiple-upcoming-conferences-6768345)
- 2026-11-02 22:46 UTC [SEC Form 4] [Chief Executive Officer Klein Lawrence Otto exercised 25,000 shares at a strike of $7.80 and sold $2,390,125 worth of shares (25,000 units at $95.60) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-klein-lawrence-otto-exercised-25000-shares-at-6767966)
- 2026-10-26 12:00 UTC [SEC Form 8-K] [SEC Form 8-K filed by Oruka Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-oruka-therapeutics-inc-6757088)
- 2026-10-26 11:00 UTC [Earnings Date] [Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis](https://www.quantisnow.com/insight/oruka-therapeutics-announces-positive-week-16-results-for-orka-001-from-6756881)
- 2026-10-25 16:00 UTC [Earnings Date] [Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026](https://www.quantisnow.com/insight/oruka-therapeutics-to-host-conference-call-to-report-week-16-6756749)
- 2026-10-21 00:42 UTC [SEC Form 4] [General Counsel Quinlan Paul T sold $706,735 worth of shares (9,000 units at $78.53) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/general-counsel-quinlan-paul-t-sold-706735-worth-of-shares-6752581)
- 2026-10-15 22:15 UTC [SEC Form 4] [Chief Medical Officer Goncalves Joana sold $523,648 worth of shares (7,000 units at $74.81) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-goncalves-joana-sold-523648-worth-of-shares-6748448)
- 2026-10-13 20:34 UTC [SEC Form 4] [Senior Vice President, Finance Agarwal Arjun sold $805,889 worth of shares (9,999 units at $80.60) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/senior-vice-president-finance-agarwal-arjun-sold-805889-worth-of-6745267)
- 2026-10-02 23:54 UTC [SEC Form 4] [Chief Executive Officer Klein Lawrence Otto exercised 25,000 shares at a strike of $7.80 and sold $2,090,593 worth of shares (25,000 units at $83.62) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-klein-lawrence-otto-exercised-25000-shares-at-6735634)
- 2026-09-23 11:00 UTC [Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing](https://www.quantisnow.com/insight/oruka-therapeutics-announces-positive-week-28-data-for-orka-001-from-6723548)
- 2026-09-21 21:38 UTC [SEC Form 4] [Senior Vice President, Finance Agarwal Arjun sold $51,035 worth of shares (533 units at $95.75) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 14,219 units (SEC Form 4)](https://www.quantisnow.com/insight/senior-vice-president-finance-agarwal-arjun-sold-51035-worth-of-6722027)
- 2026-09-21 20:57 UTC [SEC Form 4] [General Counsel Quinlan Paul T exercised 10,000 shares at a strike of $7.80 and sold $936,417 worth of shares (10,000 units at $93.64) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/general-counsel-quinlan-paul-t-exercised-10000-shares-at-a-6721903)
- 2026-09-15 23:18 UTC [SEC Form 4] [Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $734,145 worth of shares (7,947 units at $92.38) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 31,771 units (SEC Form 4) (for tax liability)](https://www.quantisnow.com/insight/chief-medical-officer-goncalves-joana-exercised-7000-shares-at-a-6716664)
- 2026-09-15 23:17 UTC [SEC Form 4] [Senior Vice President, Finance Agarwal Arjun sold $926,010 worth of shares (10,019 units at $92.43) as part of a pre-agreed trading plan and exercised 9,459 shares at a strike of $15.88, decreasing direct ownership by 4% to 14,752 units (SEC Form 4) (for tax liability)](https://www.quantisnow.com/insight/senior-vice-president-finance-agarwal-arjun-sold-926010-worth-of-6716663)
- 2026-09-15 23:15 UTC [SEC Form 4] [Chief Executive Officer Klein Lawrence Otto sold $234,681 worth of shares (2,452 units at $95.71), decreasing direct ownership by 0.26% to 923,128 units (SEC Form 4) to cover withholding tax](https://www.quantisnow.com/insight/chief-executive-officer-klein-lawrence-otto-sold-234681-worth-of-6716661)
- 2026-09-15 23:14 UTC [SEC Form 4] [General Counsel Quinlan Paul T sold $99,443 worth of shares (1,039 units at $95.71), decreasing direct ownership by 3% to 29,995 units (SEC Form 4) to cover withholding tax](https://www.quantisnow.com/insight/general-counsel-quinlan-paul-t-sold-99443-worth-of-shares-6716659)
- 2026-09-15 23:11 UTC [SEC Form 4] [Chief Operating Officer Sandler Laura Lee sold $86,713 worth of shares (906 units at $95.71), decreasing direct ownership by 0.38% to 235,478 units (SEC Form 4) (withholding tax)](https://www.quantisnow.com/insight/chief-operating-officer-sandler-laura-lee-sold-86713-worth-of-6716658)
- 2026-09-09 20:01 UTC [Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference](https://www.quantisnow.com/insight/oruka-therapeutics-to-attend-the-2026-morgan-stanley-global-healthcare-6709894)
- 2026-09-01 22:36 UTC [SEC Form 4] [Chief Operating Officer Sandler Laura Lee exercised 5,000 shares at a strike of $7.80 and sold $459,101 worth of shares (5,000 units at $91.82) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-operating-officer-sandler-laura-lee-exercised-5000-shares-at-6701963)
- 2026-09-01 22:35 UTC [SEC Form 4] [Chief Executive Officer Klein Lawrence Otto exercised 75,000 shares at a strike of $7.80 and sold $6,887,484 worth of shares (75,000 units at $91.83) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-klein-lawrence-otto-exercised-75000-shares-at-6701962)
- 2026-08-28 20:10 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Oruka Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-oruka-therapeutics-inc-6698376)
- 2026-08-28 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Oruka Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-oruka-therapeutics-inc-6697849)
- 2026-08-25 20:25 UTC [SEC Form 4] [Chief Commercial Officer Edwards Larry Todd was granted 100,000 shares (SEC Form 4)](https://www.quantisnow.com/insight/chief-commercial-officer-edwards-larry-todd-was-granted-100000-shares-6694364)
- 2026-08-25 20:10 UTC [SEC Form 3] [SEC Form 3 filed by new insider Edwards Larry Todd](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-edwards-larry-todd-6694238)
- 2026-08-24 20:06 UTC [SEC Form 8-K] [Oruka Therapeutics Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/oruka-therapeutics-inc-filed-sec-form-8-k-leadership-update-6692686)
- 2026-08-24 20:01 UTC [Leadership Update] [Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer](https://www.quantisnow.com/insight/oruka-therapeutics-appoints-todd-edwards-as-chief-commercial-officer-6692608)
- 2026-08-21 20:18 UTC [SEC Form S-3] [SEC Form S-3 filed by Oruka Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-oruka-therapeutics-inc-6691406)
- 2026-08-17 22:09 UTC [SEC Form 4] [Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $782,882 worth of shares (7,000 units at $111.84) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-goncalves-joana-exercised-7000-shares-at-a-6685526)
- 2026-08-14 21:52 UTC [SEC Form 4] [General Counsel Quinlan Paul T exercised 52,000 shares at a strike of $11.60 and sold $5,641,409 worth of shares (52,000 units at $108.49) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/general-counsel-quinlan-paul-t-exercised-52000-shares-at-a-6683831)
- 2026-08-14 21:42 UTC [SEC Form 4] [Senior Vice President, Finance Agarwal Arjun exercised 10,000 shares at a strike of $15.69 and sold $1,066,572 worth of shares (10,000 units at $106.66) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/senior-vice-president-finance-agarwal-arjun-exercised-10000-shares-at-6683811)
- 2026-08-10 20:06 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Oruka Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-oruka-therapeutics-inc-6673636)
- 2026-08-10 11:03 UTC [Public Offering] [Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://www.quantisnow.com/insight/oruka-therapeutics-reports-second-quarter-2026-financial-results-and-provides-6672621)
- 2026-08-10 11:00 UTC [SEC Form 8-K] [Oruka Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/oruka-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6672612)
- 2026-07-15 23:36 UTC [SEC Form 4] [Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $603,938 worth of shares (7,000 units at $86.28) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-goncalves-joana-exercised-7000-shares-at-a-6638720)
- 2026-07-13 21:09 UTC [SEC Form 4] [Senior Vice President, Finance Agarwal Arjun exercised 9,999 shares at a strike of $15.69 and sold $846,180 worth of shares (9,999 units at $84.63) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/senior-vice-president-finance-agarwal-arjun-exercised-9999-shares-at-6635689)
- 2026-07-02 01:30 UTC [SEC Form 4] [Director Fairmount Funds Management Llc converted options into 3,553,410 shares and sold $300,014,406 worth of shares (3,553,410 units at $84.43) (SEC Form 4)](https://www.quantisnow.com/insight/director-fairmount-funds-management-llc-converted-options-into-3553410-shares-6623959)
- 2026-07-01 23:58 UTC [SEC Form 4] [Chief Operating Officer Sandler Laura Lee exercised 5,000 shares at a strike of $7.80 and sold $472,079 worth of shares (5,000 units at $94.42) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-operating-officer-sandler-laura-lee-exercised-5000-shares-at-6623867)
- 2026-06-22 23:59 UTC [SEC Form 4] [Senior Vice President, Finance Agarwal Arjun sold $128,468 worth of shares (1,587 units at $80.95) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 15,312 units (SEC Form 4)](https://www.quantisnow.com/insight/senior-vice-president-finance-agarwal-arjun-sold-128468-worth-of-6611419)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ORKA
- Earnings history: https://www.quantisnow.com/earnings/ORKA
- Dividend history: https://www.quantisnow.com/dividends/ORKA
- Insider transactions: https://www.quantisnow.com/insiders/ORKA
- Options chain: https://www.quantisnow.com/options/ORKA
- SEC 8-K filings only: https://www.quantisnow.com/company/ORKA/8-k
- RSS and alerts for ORKA: https://www.quantisnow.com/docs/rss-feeds.md